目次

Contents

1. Executive Summary

2. Oncology Drugs Market
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms

3. Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation

4. Average Pricing Analysis

5. Market Dynamics
5.1. Growth Drivers
5.2. Restraints
5.3. Opportunity
5.4. Trends

6. Correlation & Regression Analysis
6.1. Correlation Matrix
6.2. Regression Matrix

7. Recent Development, Policies & Regulatory Landscape

8. Risk Analysis
8.1. Demand Risk Analysis
8.2. Supply Risk Analysis

9. Oncology Drugs Market Analysis
9.1. Porters Five Forces
9.1.1. Threat of New Entrants
9.1.2. Bargaining Power of Suppliers
9.1.3. Threat of Substitutes
9.1.4. Rivalry
9.2. PEST Analysis
9.2.1. Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological

10. Oncology Drugs Market
10.1. Market Size & forecast, 2019A-2030F
10.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.1.2. By Volume (Million Units) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

11. Oncology Drugs Market: Market Segmentation
11.1. By Regions
11.1.1. North America:(U.S. and Canada)
11.1.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America)
11.1.2.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe)
11.1.3.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific)
11.1.4.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa)
11.1.5.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

12. Oncology Drugs Market: Market Segmentation
12.1. By disease indication: Market Share (2020-2030F)
12.1.1. Lung Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.2. Stomach Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.3. Colorectal Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.4. Breast Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.5. Prostate Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.6. Liver Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.7. Esophagus Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.8. Cervical Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.9. Kidney Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.10. Bladder Cancer, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.11. Other Cancers, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.2. By type : Market Share (2020-2030F)
12.2.1. Chemotherapy, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.2.2. Targeted Therapy, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.2.3. Immunotherapy, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.2.4. Hormonal Therapy, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

13. Company Profile
13.1. Bayer AG
13.1.1. Company Overview
13.1.2. Company Total Revenue (Financials)
13.1.3. Market Potential
13.1.4. Global Presence
13.1.5. Key Performance Indicators
13.1.6. SWOT Analysis
13.1.7. Product Launch
13.2. Genentech, Inc.
13.3. Novartis AG
13.4. Pfizer Inc.
13.5. Bristol-Myers Squibb Company
13.6. GlaxoSmithKline plc.
13.7. Eli Lilly and Company
13.8. AstraZeneca
13.9. Sanofi
13.10. Other prominent players
Consultant Recommendation
**The above-given segmentation and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.